Regenerative Medicine Redefined
Vantage Biologics partners with forward-thinking medical practices to deliver premium, human-derived umbilical cord MSC exosome solutions — the only exosome product with a 351(a) FDA application, backed by over 900 published studies.
Growth Factors Per Treatment
Published Studies on PubMed
Only Exosome With FDA Application
The Science
Exosomes are small vesicles secreted by stem cells that contain large amounts of growth factors, cytokines, and other substances with high regenerative potential. Their unique structure allows them to fuse with other cells in the body and release their contents — including growth factors, cytokines, and miRNA — helping cells heal through transferred signaling molecules.
Unlike stem cells, exosomes do not replicate, do not contain DNA, and do not trigger an immune response — resulting in a safer product. By definition, exosome products are cell-free and contain no live cells.
Our exosomes are derived from Wharton's Jelly located inside donated umbilical cords from full-term, live births — the most robust and plentiful source of regenerative stem cells available, and the most ethically appropriate source for manufacturing exosomes.
growth factors delivered per treatment — compared to just 15-25 from a typical PRP injection.
That makes exosome therapy potentially 60 times more powerful than PRP treatment.
Benefits have been observed extending several years after completion, with some patients seeing results almost immediately and others within 2-3 months.
Why Exosomes
Platelet-rich plasma delivers roughly 15-25 growth factors to the treatment area. While established, PRP is limited in regenerative potential and requires drawing the patient's own blood each session.
Live stem cells have a relatively short lifespan once injected. In rare cases they can cause immune responses, accumulate in blood vessels, or cause random growths. Much of their therapeutic benefit actually comes from the exosomes they release.
Over 700+ growth factors per treatment. No live DNA, no immune response risk, no replication concerns. Cell-free, safe, and potentially 60x more powerful than PRP. Benefits observed lasting years.
Source Matters
The exosome market is growing rapidly, but most products are plant-based, marine-derived, or lyophilized — limiting their bioactive potential. Here's how the sources compare.
Derived from fruits, vegetables, or other plant sources. They lack human-compatible signaling molecules and have minimal clinical evidence for therapeutic applications in human tissue regeneration.
A newer entrant to the market. While novel, marine-derived exosomes lack the depth of clinical research, human biocompatibility, and the growth factor profile needed for meaningful regenerative outcomes.
Derived from Wharton's Jelly in human umbilical cords — the gold standard. Over 922 published studies. Rich in bioactive growth factors, cytokines, and signaling molecules with natural human biocompatibility. The only product with a 351(a) FDA application.
Versatile Treatment Options
Our exosome solutions can be administered through multiple methods, giving practitioners flexibility to tailor treatments to each patient's needs.
Targeted delivery directly to the treatment area — joints, spine, soft tissue, and more. Ideal for orthopedic and localized conditions.
Intravenous push or drip for systemic conditions requiring whole-body distribution of growth factors and regenerative signaling.
Inhaled delivery for pulmonary and neurological applications, allowing direct access to respiratory tissue and crossing the blood-brain barrier.
Gels, serums, and topical solutions for aesthetic procedures, wound healing, skin rejuvenation, and hair restoration protocols.
Clinical Applications
UC-MSC exosomes are being researched and applied across an extraordinary range of medical specialties and conditions.
Skin rejuvenation, wrinkle reduction, scar treatment, hair restoration, anti-aging optimization, and vaginal rejuvenation.
Osteoarthritis, meniscus tears, ACL injuries, rotator cuff injuries, plantar fasciitis, bone fractures, bone fusion, spinal injuries, and cartilage regeneration.
Traumatic brain injury, stroke, dementia, Alzheimer's, Parkinson's, multiple sclerosis, ALS, autism, epilepsy, PTSD, and peripheral nerve damage.
Congestive heart failure, coronary artery disease, hypertension, and general cardiac tissue repair and regeneration.
COPD, pulmonary fibrosis, respiratory issues, long COVID recovery, and post-vaccine complications.
Autoimmune diseases, Lyme disease, fibromyalgia, IBS, gut health, type 2 diabetes, liver disease, kidney disease, and systemic inflammation.
Muscle strains and tears, tendinitis, tendinopathy, overuse injuries, shin splints, ligament and tendon repair, and accelerated recovery.
Full-body anti-aging optimization, preventative maintenance protocols, tinnitus, glaucoma, Bell's palsy, and overall wellness enhancement.
Accelerated wound closure, scarless healing, burn treatment, tissue regeneration, and post-surgical recovery support.
Published Research
Every claim we make is grounded in published, peer-reviewed research. Here are selected studies demonstrating the therapeutic potential of UC-MSC exosomes.
Demonstrated that UC-MSC exosomes integrate into human dermal fibroblasts, promoting cell migration and synthesis of Collagen I and Elastin — essential proteins for skin rejuvenation.
Kim et al. · Biochem Biophys Res Commun · 2017
View on PubMed →Found that UC-MSC exosomes stimulate fibroblast proliferation, regulate extracellular matrix synthesis, and reduce melanin production — applications in scar reduction and skin lightening.
Kee et al. · Int J Nanomedicine · 2025
View on PubMed →First study to elucidate how UC-MSC exosomes achieve scarless healing through miR-185-5p, precisely remodeling collagen ratios via the RhoA/YAP signaling axis.
Yang et al. · Advanced Science · 2026
View on PubMed →hUCMSC-Exos restored motor coordination and cognitive function through enhanced remyelination and reduced neuroinflammation (TNF-α, IL-6) while elevating BDNF.
Peng et al. · Stem Cell Rev Rep · 2026
View on PubMed →UC-MSC exosomes modulated immune response and promoted corneal epithelial regeneration, reestablishing immune cell balance and reducing inflammation in dry eye disease.
Gong et al. · Scientific Reports · 2026
View on PubMed →Comprehensive review of MSC exosome applications in cardiac repair, highlighting their multipotent differentiation potential and favorable safety profile for heart tissue regeneration.
Azimian Zavareh et al. · Front Pharmacol · 2026
View on PubMed →These represent a small selection from 922+ published studies on UC-MSC exosomes available on PubMed.
Why Vantage Biologics
Vantage Biologics is a regenerative medicine consulting firm specializing in premium UC-MSC exosome solutions. We partner with medical practices to bring the highest standard of exosome technology to their patients.
Every product we represent is backed by published, peer-reviewed research, third-party tested by Eurofins, and manufactured in an ISO-5, FDA approved facility. We don't sell hype — we deliver science.
We don't just supply products. We partner with your practice to educate staff, develop treatment protocols, and ensure successful implementation from day one.
Our exosome product is the only one with a 351(a) FDA application — a classification exclusively for products that do not contain tissue or DNA. This is a critical differentiation from every other product on the market.
Get Started
Schedule a consultation to learn how UC-MSC exosome solutions can differentiate your practice and deliver premium outcomes for your patients.